About

223 million patients. A treatment ecosystem built on false safety.

Atopic dermatitis is the #1 skin disease by disability-adjusted life years. It affects 11.1% of children and 6.3% of adults globally. Yet every approved treatment carries a hidden crisis — from steroid withdrawal syndrome to biologic-triggered fungal flares.

Topical Corticosteroids

  • 79% of adult eczema patients report TSW symptoms
  • 81% report intense emotional fluctuations during TSW
  • 80% experience insomnia during withdrawal
  • 8% experience TSW symptoms for over 5 years after stopping

Biologics & JAK Inhibitors

  • 40% real-world ocular surface disease with dupilumab
  • 10–44% develop Malassezia fungal flares after IL-4/IL-13 blockade
  • 8.5% conjunctivitis with lebrikizumab vs. 2.5% placebo
  • JAK inhibitors carry a BLACK BOX warning

Broad immunosuppressants such as methotrexate, cyclosporine, and systemic steroids affect the whole immune system and are associated with serious potential adverse effects, including infections, organ toxicity, metabolic complications, and increased cancer risk.

Targeted biologics and JAK inhibitors have improved efficacy for many, but meta-analyses and cohort studies show an overall increased infection risk with these agents, including herpes and fungal infections in patients on JAK inhibitors and higher fungal infection rates across biologics as a class; JAK inhibitors in particular carry warnings for serious infections, blood clots, cardiovascular events, and malignancy.

That's why Kynova Therapeutics is focused on developing the next generation of treatment that targets the root biology of atopic dermatitis rather than just managing flares. By designing injectable peptide candidates that directly address chronic inflammation, barrier dysfunction, and disrupted repair pathways, we aim to move beyond broad immunosuppression and towards a more precise, skin-centric approach. Our goal is to build therapies that are grounded in the underlying mechanisms of disease and thoughtfully engineered for long-term use, so patients can aspire to control that feels more effective, more sustainable, and less compromising than the options they face today.